thiodigalactoside has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Francuz, T; Gallego-Colon, E; GrochoĊa, I; Kubeczko, M; Ruiz-Agamez, N; Wdowiak, K; Wojnar, J | 1 |
| Albert, S; Astorgues-Xerri, L; Faivre, S; Neuzillet, C; Raymond, E; Riveiro, ME; Serova, M; Tijeras-Raballand, A | 1 |
| Blanchard, H; Clark, AM; Gabutero, E; Ito, K; Neo, SY; Onturk, S; Ralph, SJ; Stannard, K | 1 |
3 review(s) available for thiodigalactoside and Neoplasms
| Article | Year |
|---|---|
Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.
Topics: Calixarenes; Clinical Trials as Topic; Galactose; Galectins; Humans; Mannans; Neoplasms; Pectins; Peptides; Polysaccharides; Thiogalactosides | 2018 |
Unraveling galectin-1 as a novel therapeutic target for cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Calixarenes; Galectin 1; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Peptides; Signal Transduction; Thiogalactosides; Up-Regulation | 2014 |
Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment.
Topics: Animals; Cell Hypoxia; Galectin 1; Humans; Immune Tolerance; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; T-Lymphocytes; Thiogalactosides; Tumor Microenvironment | 2012 |